Abstract
We often confront the issue of advising otherwise healthy breast cancer survivors, who are likely to be long-term users of aromatase inhibitors (AIs), on the maintenance of bone health. Although our approach is largely based on the American Society of Clinical Oncology (ASCO) guidelines, we outline some practical considerations to this common problem.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
